Furthermore, suppression of HDGF increased gefitinib efficacy in resistant NSCLC cells both in vitro and in vivo, suggesting that HDGF is a potential target to overcome gefitinib resistance. This evidence concerns the gene HDGF and non-small cell lung carcinoma.